KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Liabilities (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Non-Current Liabilities for 13 consecutive years, with $24.9 million as the latest value for Q2 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $24.9 million in Q2 2025 year-over-year; TTM through Jun 2025 was $24.9 million, a N/A change, with the full-year FY2024 number at $54.8 million, up 45.17% from a year prior.
  • Other Non-Current Liabilities was $24.9 million for Q2 2025 at Halozyme Therapeutics, down from $54.8 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $130.0 million in Q2 2022 to a low of $544000.0 in Q4 2021.
  • A 5-year average of $39.0 million and a median of $30.6 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 84.3% in 2021, then soared 5908.46% in 2022.
  • Halozyme Therapeutics' Other Non-Current Liabilities stood at $544000.0 in 2021, then skyrocketed by 5908.46% to $32.7 million in 2022, then grew by 15.4% to $37.7 million in 2023, then skyrocketed by 45.17% to $54.8 million in 2024, then plummeted by 54.53% to $24.9 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Other Non-Current Liabilities are $24.9 million (Q2 2025), $54.8 million (Q4 2024), and $37.7 million (Q4 2023).